Abstract: The present invention relates to a compound represented by the following formula (I): A[B—(C)v]w??(I), wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of such compounds in cosmetic and therapeutic applications. The invention also relates to the use of such compounds for reducing photodegradation and/or photoinstability of pharmaceuticals and cosmetics. The invention further relates to a material comprising a support and such a compound adhered to said support.

Abstract: The present invention relates to a compound represented by the following formula (I): A[B—(C)v]w, wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of such compounds in cosmetic and therapeutic applications. The invention also relates to the use of such compounds for reducing photodegradation and/or photoinstability of pharmaceuticals and cosmetics. The invention further relates to a material comprising a support and such a compound adhered to said support.

Abstract: The present invention relates to a set of particles comprising at least one bioadhesive particle of formula (I): {A-[(B)n-C]m}.X??(I), in which A represents a polymer core, B represents a linear linker, C represents a functional group, n is 0 or 1, and m is an integer from 1 to 1025, and where said bioadhesive particle encapsulates or is attached to at least one active agent X. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of the set of particles in medicine, in particular for treating and/or preventing skin, mucosa, or eye cornea diseases or conditions.

Abstract: The present invention relates to pharmaceutical compositions comprising a drug for topical administration, e.g. a TLR7 modulator. More specifically it relates to a pharmaceutical composition comprising a benzo[f][1,7]naphthyridine derivative.

Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.

Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.

Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.

Abstract: The invention relates to pharmaceutical compositions suitable for oral administration in the form of edible films comprising diclofenac.

Abstract: Compositions intended for the percutaneous administration of physiologically active agents, e.g. drugs or a veterinary agents, are disclosed. Sasd compositions are characterized by having an exeefenf long term efficacy due to their ability to form a long-lasting film on the skin.

Abstract: The invention relates to coated tablets comprising the pharmaceutically active substance diclofenac. Said tablets further comprise a single film coating.

Abstract: The invention relates to certain nicotine chewing gums that provide for a high rate of buccal absorption and high plasma concentrations, in particular over the first 10 minutes after administration, in a subject willing to quit smoking.

Abstract: The invention relates to beneficial topical pharmaceutical compositions comprising the diclofenac diethylammonium salt in unusually high amounts. Said compositions represent opaque emulsion-gels with unique properties such as high skin penetration, no irritation, high stability, complete dissolution of the active and high pain relief.

Abstract: The invention relates to a certain oral dosage form providing absorption of the drug diclofenac in an ultrafast manner.

Abstract: The invention relates to pharmaceutical compositions suitable for oral administration in the form of edible films comprising diclofenac.

Abstract: The invention relates to coated tablets comprising the pharmaceutically active substance diclofenac. Said tablets are characterized by a special, very beneficial coating based on hydroxypropyl methylcellulose.

Abstract: The invention relates to pharmaceutical compositions adapted to nasal administration. The nasal formulations of the invention are characterized inter alia by having excellent moisturizing properties and not requiring a preservative.

Abstract: The present invention provides for the use of a polymer of the acrylic type as a disintegration agent.

Abstract: A subject of the present Application is the use of at least one methacrylic acid copolymer of type C according to the USP/NF as an agent or co-agent allowing the improvement of the disintegration speed of a tablet while allowing a tablet with a good cohesion to be obtained, in particular by simple direct compression. It relates in particular to the use of at least one methacrylic acid copolymer of type C according to the USP/NF as an agent or co-agent allowing or participating in the disintegration of a tablet, as well as a production process for tablets involving the use of at least one copolymer as a disintegration agent or co-agent in a tablet.

Abstract: The invention relates to bioadhesive compounds in the form of multilayers and having at least one bioadhesive layer with the total charge of bioadhesive material wherein the bioadhesive layer is directly compressible during the production of the tablet, and also containing at least one layer with the total charge of active principals.

Abstract: The present invention relates to a new mucoadhesive pharmaceutical composition which makes possible the prolonged release of active pharmaceutical principles in the buccal cavity or via the transmucosal route.